Celine Halioua On The Science and Business of Making Dogs Live Longer

Most biotech founders chase human applications from day one. Celine Halioua took the opposite bet: start with dogs, perfect the science, then scale to humans. Her company Loyal is developing FDA-approved drugs to extend canine lifespan, treating our four-legged companions as the stepping stone to human longevity therapeutics. The strategy sounds backwards until you understand the regulatory math that makes human longevity drugs nearly impossible to develop.

Halioua's path to dog longevity began with an existential crisis. "I got into college for art school. Summer before I started, had a total, like, existential crisis, realized that, you know, biology in our bodies and health is actually the determinant of our free will and switched to neuroscience," she explains. That overnight pivot from art to aging biology led to years of research before she realized the fundamental problem with human longevity drugs: the patent system creates an impossible catch-22.

Here's the trap. Developing any drug takes 10-15 years and costs hundreds of millions of dollars. Patents expire 20 years from filing. For disease-specific drugs, this timeline works because you can show clear efficacy against a defined condition relatively quickly. But longevity drugs target the aging process itself, which unfolds over decades. By the time you could prove a human longevity drug actually extends lifespan, your patent would be expired and your billion-dollar investment would be worthless.

Dogs solve this timing problem elegantly. They age roughly seven times faster than humans, compressing a longevity study from decades to years. More importantly, the FDA already has a regulatory pathway for animal drugs, while human longevity therapeutics remain in regulatory limbo. "I think we have a little bit of a catch 22 with what kind of drug you develop for human longevity," Halioua notes, because regulators still haven't defined what endpoints would prove anti-aging efficacy in humans.

The business model reflects biotech's unique risk profile compared to software startups. While software companies typically focus on scaling a single product, "very different about biotech, versus software is you in software, like, generally speaking, you'll, like, start as a product. You'll, like, scale it out, and maybe you'll have" additional products later. Biotech requires multiple shots on goal from the beginning because any single drug candidate might fail in trials.

This multi-product approach creates what Halioua calls milestone-based fundraising. "Fundraising becomes based on milestones on the way to that approval, in our case, that increase the probability that that vision of a future that we're creating is going to occur." Each successful trial phase doesn't just advance the science; it de-risks the entire business model. The regulatory hurdles that make biotech so difficult also create massive competitive moats once you succeed.

The fundraising journey itself followed an unusual pattern. Early rounds were surprisingly manageable because "it becomes easy when a very complicated idea is diligent so well over years that it becomes obvious," Halioua explains. The challenge came later, in growth rounds, when investors had to bet bigger on unproven regulatory pathways.

But the real insight isn't about fundraising mechanics. It's about market sequencing in deep tech. Loyal isn't really a dog company that might expand to humans someday. It's a human longevity company that recognized dogs as the only viable entry point. The pet market provides immediate revenue and proof-of-concept while building the regulatory expertise and manufacturing capabilities needed for eventual human applications.

This strategy reveals something broader about how breakthrough technologies actually reach market. The most direct path often isn't viable. Instead, successful founders find adjacent markets where the same underlying technology can prove itself under more favorable conditions. Dogs give Halioua everything she needs: faster aging, established regulatory pathways, and a market that cares more about lifespan extension than the FDA's cautious approach to human anti-aging claims.

Watch for other longevity startups to follow similar paths. Human applications remain the ultimate prize, but regulatory reality may force most serious longevity companies to prove themselves in animal models first. The real question isn't whether Loyal can extend dog lifespans. It's whether their regulatory playbook becomes the template for bringing human longevity drugs to market at all.